Daniel Keizman: Clinical Trials

1 trial sponsored by Daniel Keizman, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. .

Follow Daniel Keizman: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Serum Gal-3 level, blood count and chemistry included liver function - Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer
RecruitingDaniel Keizman3002025-12-032026-03-20

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Kidney Neoplasms (1)

Interventions

Blood Cell Count (1)

Countries

Israel (1)